Balefire LLC trimmed its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 35.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,216 shares of the exchange traded fund’s stock after selling 7,662 shares during the quarter. Balefire LLC’s holdings in SPDR S&P Biotech ETF were worth $2,242,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in the stock. Wedmont Private Capital bought a new stake in SPDR S&P Biotech ETF during the 3rd quarter valued at about $684,000. Breakwater Capital Group grew its stake in SPDR S&P Biotech ETF by 2.5% in the 3rd quarter. Breakwater Capital Group now owns 20,157 shares of the exchange traded fund’s stock worth $3,178,000 after acquiring an additional 501 shares in the last quarter. First Heartland Consultants Inc. increased its position in shares of SPDR S&P Biotech ETF by 8.6% during the third quarter. First Heartland Consultants Inc. now owns 10,541 shares of the exchange traded fund’s stock worth $1,662,000 after acquiring an additional 832 shares during the period. Galvin Gaustad & Stein LLC purchased a new position in shares of SPDR S&P Biotech ETF during the third quarter worth approximately $317,000. Finally, Overbrook Management Corp bought a new stake in shares of SPDR S&P Biotech ETF during the third quarter valued at approximately $323,000.
SPDR S&P Biotech ETF Trading Up 3.0%
Shares of NYSEARCA XBI traded up $4.48 during trading hours on Friday, reaching $153.77. The stock had a trading volume of 12,125,512 shares, compared to its average volume of 9,168,406. The firm has a market cap of $10.05 billion, a price-to-earnings ratio of 11.47 and a beta of 0.83. The business’s fifty day moving average price is $158.46 and its two-hundred day moving average price is $145.91. SPDR S&P Biotech ETF has a 52-week low of $103.43 and a 52-week high of $169.89.
SPDR S&P Biotech ETF Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Recommended Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
